The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.

Brandon J WebbRachel HarringtonJason SchwartzJennifer KammererJames SpaldingEdward LeeBart DoddsStephanie KaufusiBruce E GoodmanSean D FirthGreta MartinJeffrey SorensenDaanish Hoda

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2018)

Despite early preemptive antiviral treatment, CMV-I impacts clinical outcomes and cost after HSCT, but the impact on cost is less pronounced in allogeneic HSCT recipients compared with autologous HSCT recipients.

Keyphrases

hematopoietic stem cell
kidney transplantation
bone marrow
stem cell transplantation
acute myeloid leukemia
stem cells
mesenchymal stem cells
combination therapy
platelet rich plasma
high dose
postoperative pain